Laguna Hills, CA-based Volcano Therapeutics has signed a letter of intent to acquire the global intravascular ultrasound and functional measurement businesses of Jomed, a high-tech medical research company headquartered in Helsingborg, Sweden. Bankruptcy
Laguna Hills, CA-based Volcano Therapeutics has signed a letter of intent to acquire the global intravascular ultrasound and functional measurement businesses of Jomed, a high-tech medical research company headquartered in Helsingborg, Sweden. Bankruptcy is forcing Jomed to divest its assets, some of which were sold to Abbott Laboratories in June. The company plans to sell the remainder in the coming months. Volcano Therapeutics has tagged several as complementary to its efforts to develop products for the detection and treatment of atherosclerosis and vulnerable plaques in the coronary and peripheral arteries. Jomed's IVUS technology is synergistic with Volcano's Virtual Histology IVUS system, recently demonstrated at the Paris Course on Revascularization, according to Scott Huennekens, Volcano president and CEO. The California company's intravascular thermography catheter products also promise to integrate well with the pressure catheter and flow wire interventional products of Jomed's functional measurement business, he said.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.